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A B S T R A C T
Background: Deadly emerging infectious pathogens pose an unprecedented challenge to health systems
and economies, especially across Africa, where health care infrastructure is weak, and poverty rates
remain high. Genomic technologies are vital for enhancing the understanding and development of
intervention approaches against these pathogens, including Ebola and the novel coronavirus disease
2019 (COVID-19).
Discussion: Africa has contributed few genomes of severe acute respiratory syndrome-coronavirus 2
(SARS-CoV-2) to the global pool in growing open access repositories. To bridge this gap, the Africa Centre
for Disease Control and Prevention (ACDC) is coordinating continent-wide initiatives to establish
genomic hubs in selected well-resourced African centres of excellence. This will allow for standardisation
and efficient and rapid data generation and curation. However, the strategy to ensure capacity for high-
throughput genomics at selected hubs should not overshadow the deployment of portable, field-friendly
and technically less demanding genomics technologies in all affected countries. This will enhance small-
scale local genomic surveillance in outbreaks, leaving validation and large-scale approaches to be taken
at central genomic hubs.
Conclusion: The ACDC needs to scale-up its campaign for government support across African Union
countries to ensure the sustainable financing of its strategy for increased pathogen genomic intelligence
and other interventions in current and inevitable future epidemics in Africa.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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The novel coronavirus disease 2019 (COVID-19), a viral
outbreak caused by the severe acute respiratory syndrome-
coronavirus 2 (SARS-CoV-2), first arose in Wuhan, China, in
December 2019, and it was declared a Public Health Emergency of
International Concern on January 30, 2020 (WHO, 2020b). Seven
months into the COVID-19 pandemic, the number of cumulative
cases continues to steadily increase. As of August 3, 2020,
17,660,523 cases had been detected, with 680,894 total deaths
globally. Africa has borne 4.5% of global morbidity and 2.0% of
fatalities (WHO, 2020a).* Corresponding author.
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COVID-19 has placed an unparalleled burden on the health
systems and economies of all affected countries, with a projected
serious impact on African countries that are already saddled with
weak health care provision and economic systems. Apart from the
immediate economic losses, there are considerable costs associat-
ed with the containment of the pandemic, from laboratory testing
to personal protective equipment, treatment and personnel costs.
Mass testing is being advocated, and this requires molecular
techniques, the current gold standard for COVID-19 detection, as
recommended by the World Health Organisation (WHO) (WHO/
Africa, 2020). However, these polymerase chain reaction-based
tests do not provide information on the origin of an infection,
possible mutations in the virus or transmission links in clusters of
infection. Monitoring the evolution of the virus and transmission
networks is essential for containment strategies, and this requires
obtaining genomic data by sequencing viral isolates from infectedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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tools can provide additional data to refine strategies to fight against
COVID-19. Examination of the nucleic acid sequences of a virus
enables detailed understanding of its genetic content, evolution
and diversity both within and between local communities. The
information obtained from sequencing is also essential in the
design of effective vaccines, drugs, efficacy monitoring and
transmission studies. As the virus continues to evolve in African
populations, African countries and the Africa Centre for Disease
Control and Prevention (ACDC) must facilitate investment in costly
laboratory technologies that will ensure that the strains of SARS-
CoV-2 circulating in Africa are included in the design of new
interventions.
African SARS-CoV-2 genomes in publicly available sequence
databases
While SARS-CoV-2 sequence data are an integral part of the
information used for making decisions on other continents (Lu et al.,
2020; Zhu et al., 2020), Africa has yet to integrate this information
into our decision making for managing COVID-19 outbreaks within
the continent. This is primarily due to limited skillsets and
infrastructural deficiencies (Devex, 2020). To the present, only
900 SARS-CoV-2 genome sequences from 14 African countries have
been uploaded out of a total of 62,267 whole-genome sequences in
GISAID (GISAID, 2020), an online database for the rapid sharing of
viral genomes and clinical and epidemiological data. Africa has
recorded approximately 642,387 cases and close to 10,789 deaths
from COVID-19 (WHO, 2020a). On a global scale, this significantly
outweighs the available African SARS-CoV-2 genomes, putting the
continent at disadvantage in global genetic epidemiology studies of
SARS-CoV-2 and in consideration for the design of vaccines that
could provide broad potency against all virus strains circulating in
the continent. The above narrative could be different if each country
appreciated the need for genetic data and deliberatelyempowered at
least one molecular laboratory involved in COVID-19 detection and
diagnostics with sequencing technologies. The transition to se-
quencing viral genomes could adopt cost-effective, easily deployable
and portable sequencing platforms with less restricted access to
reagents and readily available protocol-sharing global networks.
During an epidemic or a pandemic, most countries close their
land borders and airspace to restrict movement and curb the
spread of the infection. If viral sequencing platforms are not
available in a country, it must rely on shipping samples to
laboratories elsewhere to generate sequences. Doing so allows
real-time contributions to global sequencing challenging and
unrealistic. Therefore, while ACDC aims for a coordinated,
centralised approach to high-throughput next-generation se-
quencing using platforms such as the Next-seq and Hi-Seq, the
generation of moderate-quality data using Miseq, capillary
electrophoresis and Nanopore technology should be prioritised.
This model has been tested in the United Kingdom with reported
success (GenomicsEngland, 2017).
Biomedical research challenges impeding epidemic response in
Africa
A lack of concerted financial commitment, skilled personnel
and advanced infrastructure are top amongst the many hurdles
facing biomedical science research in Africa (Omoleke et al., 2018;
Gilbert et al., 2020). Unlike in the global North, African capacities
are heterogeneous, with wide differences between most sub-
Saharan African countries and South Africa, for example. Moreover,
research activities are little coordinated across borders, disallow-
ing meaningful continental approaches. This is largely driven by
lack of political will and buy-in by various African governments,which continue to consider investments in advanced scientific
technologies as low priority despite the large burden of infectious
diseases. The cost of acquiring and maintaining new technologies
such as Next Generation sequencing platforms remain relatively
high and outweighs other interventions. For instance, sequencing
the genome of a virus or other pathogen can cost tens to several
hundreds of dollars, depending on the sequencing platform used,
the number of samples available and the depth of data required
(Weymann et al., 2017). At the moment, direct budgeting and
investment by African governments in medical research remains
minimal, despite the pledge signed by all countries in the African
Union to commit 2% GDP to investment in research, under the
auspices of the ACDC designated body for coordinating disease
control across the continent. Beyond data-generating platforms,
there is also an acute shortage of expertise in genetic and genomic
data analysis and interpretation for translation into public health
interventions. This lack of trained human capacity has resulted in
heavy reliance on research collaborators and donor funding from
the global North for limited quality and few valid data outputs.
Hence, the benefit of using genetic epidemiology data in real-time
to inform policy is currently largely unrealistic.
Example institutions in Africa with impactful genomics
platforms
Despite the challenges within the continent, there are a small
number of medical research centres or institutions in Africa that are
changing the narrative. These have been largely funded by external
donors, including the NIH, World Bank, Wellcome Trust and the
African Academy of Science. Taking West Africa as an example, the
following institutions have established genomics platforms with
evidence of data generation in publications or deposition in open
access repositories: The Medical Research Council Unit, The Gambia
at London School of Hygiene and Tropical Medicine (MRCG-LSHTM);
West African Centre for Cell Biology and Infectious Disease
Pathogens (WACCBIP), University of Ghana; Institute Pasteur Dakar,
Senegal; Malaria Research and Training Center (MRTC), Mali; The
African Center of Excellence in Genomics of Infectious Pathogens
(ACEGIP), Nigeria. In Central Africa, genomics centres are almost
entirely absent, with the exception of Institut National de Recherche
Biomèdicale DRC. Eastern and Southern Sub-Saharan Africa have
many more institutions, including a large number of public, private
and commercial platforms in South Africa. These institutions,
supported by funders, are investing significantly in infrastructural
and human capacity development. They provide platforms for
teaching and research and are building momentum for advanced
molecular bioscience research in West and Central Africa.
Emerging coordination and networking of genomics and
testing hubs
The ACDC has taken up a coordinated continental perspective to
definestrategies that can address some of thechallenges impeding the
derivation of full benefits from currently available technologies that
will facilitate interventions against SARS-CoV-2 and future emerging
pathogens (ACDC, 2020). The larger goal is to set up centralised
genomics laboratory hubs, coordinated by the Pathogen Genomics
Intelligence Institute (ACDC, 2020). The main goal is to strengthen and
link health systems with these institutions for the effective surveil-
lance, detection, tracking and monitoring of outbreaks before they
occur across the continent. To substantiate their efforts, Illumina, a
leading genomics company, has donated $1.4 million in equipment,
software and reagents to the region through the ACDC (Devex, 2020).
Recently, the African Union Commission/ACDC formally launched
the Partnership to Accelerate COVID-19 Testing (PACT) on June 4, 2020.
The goals of PACT are to improve testing for COVID-19, enhance the
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procurementsystematACDCanddeployonemillioncommunityhealth
workerstoperformcontacttracingofconfirmedcasesatthecommunity
level (ACDC, 2020). As this initiative is coming in the middle of an
ongoing outbreak, the impact of its interventions might not be manifest
in the short term. However, the ACDC, as a new institution, could take
advantage of the experience of already established centres such as the
EuropeanandAmericanCDCstoputintoplaceregulationandstructures
that will facilitate and sustain cross-border collaborative platforms for
more robust epidemic preparedness, readiness and response across the
continent in the near future.
Conclusion and recommendations
Despite the efforts of ACDC to promote centralised genomic
hubs, a situational analysis of continental needs and priority areas
in epidemic preparedness and genomic intelligence is necessary.
The current state of institutions, infrastructure and human
resources for data generation, management and analysis needs
urgent attention. To respond to epidemics such as COVID-19,
genomic data generation for real-time decision making could be
enhanced by the adoption and decentralised application of small,
portable and easily operated experimental tools such as the Oxford
Nanopore technology-MinION sequencer, Illumina MiniSeq or the
BGI-DNBSeq across all countries. These easily deployable, user-
friendly field-based technologies were instrumental in the
sequencing of the Ebola virus (EBOV) during the last outbreak in
West and Central Africa (Arias et al., 2016; Hoenen et al., 2016;
Quick et al., 2016). The data generated were useful for strategizing
and ensuring the efficacy of interventions, including tracking and
stopping the spread of EBOV and evaluating vaccine efficacy.
Already established genomics hubs strategically located in the
west, east, south and north of the continent could collate samples
from each country for validation and high-throughput production
of data because they have the requisite technical expertise and
infrastructure. In this regard, standardised operating procedures,
quality-assured operations and data curation strategies can be
assured and disseminated as well. This can provide a benchmark
for future comparative data analysis.
To build on its current gains, the ACDC should engage in a massive
campaign for stronger political commitment African Union member
states to support funding for genomics as a tool for the surveillance
and monitoringof disease outbreaks. Betterengagement approaches
will enable government buy-in and ensure the financial strength
and sustainability of established genomics institutions for rapid
containment of emerging infectious disease epidemics.
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